Co-administered low-molecular-weight oral drugs

The term 'Co-administered low-molecular-weight oral drugs' does not refer to a specific biological target, such as a receptor or enzyme, but is instead a descriptive category used in clinical pharmacology to identify various small-molecule medications taken concurrently by a patient (FDA, 2020). These drugs are generally defined by a molecular weight of less than 900 Daltons, which facilitates oral bioavailability and systemic distribution (Lipinski, 2001). In the context of drug development, this grouping is critical for evaluating drug-drug interactions (DDIs), as a primary investigational drug may interfere with the absorption, distribution, metabolism, or excretion (ADME) of these co-administered substances (EMA, 2017). Such interactions often occur through the modulation of Cytochrome P450 enzymes or drug transporters like P-glycoprotein, potentially leading to adverse effects or loss of efficacy (StatPearls, 2023). Consequently, identifying and monitoring these co-administered agents is a standard requirement in clinical trial protocols to ensure patient safety and the integrity of pharmacokinetic data.

Other names

Concomitant medicationsCo-medicationsSmall molecule oral drugsConcomitant oral therapiesBackground oral therapy

Not applicable